Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Chief Accounting Officer | October 04, 2016 | October 06, 2016 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | SVP, Finance and CAO | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date October 04, 2016 · Filed October 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,839 |
Reported balance
After 2016-10-04 transaction · row 1
1 source rowRow 1 · 2016-10-04 · Grant · Acquired 1,839 · Balance 1,839 F1: Shares are represented by restricted stock units. Shares of restricted common stock vest in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.19 · Expires 2026-10-04 | Direct | 5,856 |
Reported balance
After 2016-10-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-04 · Grant · Acquired 5,856 · Balance 5,856 F2: The option vests in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are represented by restricted stock units. Shares of restricted common stock vest in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017.
F2: The option vests in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,852 |
Ending reported balance
After 2026-08-06 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-08-06 · Sale · Disposed 1,274 · Balance 14,878 F1: This transaction was executed in multiple trades at prices ranging from $258.77 to $259.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2026-08-06 · Sale · Disposed 901 · Balance 13,977 F2: This transaction was executed in multiple trades at prices ranging from $259.97 to $260.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-08-06 · Sale · Disposed 810 · Balance 13,167 F3: This transaction was executed in multiple trades at prices ranging from $261.00 to $261.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-08-06 · Sale · Disposed 213 · Balance 12,954 F4: This transaction was executed in multiple trades at prices ranging from $262.26 to $262.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-08-06 · Sale · Disposed 620 · Balance 12,334 F5: This transaction was executed in multiple trades at prices ranging from $263.39 to $264.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-08-06 · Sale · Disposed 482 · Balance 11,852 F6: This transaction was executed in multiple trades at prices ranging from $264.91 to $265.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-08-06 · Exercise / conversion · Acquired 404 · Balance 12,256 Row 8 · 2026-08-06 · Exercise / conversion · Acquired 1,205 · Balance 13,461 Row 9 · 2026-08-06 · Exercise / conversion · Acquired 736 · Balance 14,197 Row 10 · 2026-08-06 · Sale · Disposed 404 · Balance 13,793 Row 11 · 2026-08-06 · Sale · Disposed 1,205 · Balance 12,588 Row 12 · 2026-08-06 · Sale · Disposed 736 · Balance 11,852 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $179.66 · Expires 2030-05-29 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-08-06 · Exercise / conversion · Disposed 404 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 402 |
Reported balance
After 2026-08-06 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-06 · Exercise / conversion · Disposed 1,205 · Balance 402 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 736 |
Reported balance
After 2026-08-06 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-06 · Exercise / conversion · Disposed 736 · Balance 736 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $258.77 to $259.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $259.97 to $260.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $261.00 to $261.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $262.26 to $262.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $263.39 to $264.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $264.91 to $265.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 736 | $0.00 Strike: $208.44 | $0.00 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · derivative · entry 15 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 736 Underlying: Common Stock · 736 shares Expires 2034-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,205 | $0.00 Strike: $194.12 | $0.00 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · derivative · entry 14 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402 Underlying: Common Stock · 1,205 shares Expires 2033-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 404 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · derivative · entry 13 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 404 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 736 | $258.53 | $190,278.08 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 12 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,852 Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,205 | $258.53 | $311,528.65 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 11 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,588 Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 404 | $258.53 | $104,446.12 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 10 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,793 Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 736 | $208.44 | $153,411.84 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 9 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 1,205 | $194.12 | $233,914.60 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 8 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 404 | $179.66 | $72,582.64 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 7 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 482 | $265.17 | $127,811.94 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 6 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,852 F6 · price: This transaction was executed in multiple trades at prices ranging from $264.91 to $265.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 620 | $263.94 | $163,642.80 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 5 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,334 F5 · price: This transaction was executed in multiple trades at prices ranging from $263.39 to $264.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 213 | $262.37 | $55,884.81 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 4 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,954 F4 · price: This transaction was executed in multiple trades at prices ranging from $262.26 to $262.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 810 | $261.45 | $211,774.50 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,167 F3 · price: This transaction was executed in multiple trades at prices ranging from $261.00 to $261.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 901 | $260.63 | $234,827.63 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,977 F2 · price: This transaction was executed in multiple trades at prices ranging from $259.97 to $260.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,274 | $259.07 | $330,055.18 |
DisclosureSEC source: 0001100682-26-000124 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,878 F1 · price: This transaction was executed in multiple trades at prices ranging from $258.77 to $259.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 31, 2026 Filed Jun 2, 2026 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 48 | $180.71 | $8,674.08 |
DisclosureSEC source: 0001100682-26-000095 · form4.xml · nonDerivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,152 Read SEC document |
| May 30, 2026 Filed Jun 2, 2026 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 152 | $180.71 | $27,467.92 |
DisclosureSEC source: 0001100682-26-000095 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,837 | $180.71 | $331,964.27 |
DisclosureSEC source: 0001100682-26-000095 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,352 F1 · shares: Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 37 | $156.73 | $5,799.01 |
DisclosureSEC source: 0001100682-26-000077 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,515 Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 50 | $160.30 | $8,015.00 |
DisclosureSEC source: 0001100682-26-000077 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · SVP, Finance and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,552 Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 526 | $211.68 | $111,343.68 |
DisclosureSEC source: 0001100682-26-000008 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP, CAO, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,602 Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000008 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP, CAO, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,128 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023. Read SEC document |
| November 06, 2025 Filed Nov 7, 2025 21:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,926 | $170.88 | $499,994.88 |
DisclosureSEC source: 0001100682-25-000045 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP, CAO, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,460 F1 · shares: 50% of the unvested restricted stock units vest on November 6, 2026, with the remaining 50% vesting on November 6, 2027. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 225 | $135.63 | $30,516.75 |
DisclosureSEC source: 0001127602-25-016548 · form4.xml · nonDerivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,534 Read SEC document |
| May 31, 2025 Filed Jun 3, 2025 20:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 48 | $135.63 | $6,510.24 |
DisclosureSEC source: 0001127602-25-016548 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,759 Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:55 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,064 | $135.63 | $279,940.32 |
DisclosureSEC source: 0001127602-25-016548 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,807 F1 · shares: Unvested restricted stock units vest annually on: May 30, 2026; May 30, 2027; May 30, 2028; May 30, 2029. Read SEC document |
| May 28, 2025 Filed May 29, 2025 21:01 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 25 | $138.65 | $3,466.25 |
DisclosureSEC source: 0001127602-25-015897 · form4.xml · nonDerivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,743 Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:01 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 37 | $136.73 | $5,059.01 |
DisclosureSEC source: 0001127602-25-015897 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,768 Read SEC document |
| May 26, 2025 Filed May 29, 2025 21:01 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 50 | $136.73 | $6,836.50 |
DisclosureSEC source: 0001127602-25-015897 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,805 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 282 | $165.57 | $46,690.74 |
DisclosureSEC source: 0001127602-25-002719 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,855 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 811 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-002719 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,137 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 27, 2022. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 21:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,472 | $208.44 Strike: $208.44 | $306,823.68 |
DisclosureSEC source: 0001127602-24-017327 · form4.xml · derivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,472 Underlying: Common Stock · 1,472 shares Expires 2034-05-31 F2 · shares: Stock options vest as follows: 368 on May 31, 2025, 368 on May 31, 2026, 368 on May 31, 2027, and 368 on May 31, 2028. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 21:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 648 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017327 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,326 F1 · shares: Unvested restricted stock units vest as follows: 162 on May 31, 2025, 162 on May 31, 2026, 162 on May 31, 2027, and 162 on May 31, 2028. Read SEC document |
| May 29, 2024 Filed May 29, 2024 21:51 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 36 | $214.51 | $7,722.36 |
DisclosureSEC source: 0001127602-24-016822 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,678 Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 24 | $217.21 | $5,213.04 |
DisclosureSEC source: 0001127602-24-016806 · form4.xml · nonDerivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,714 Read SEC document |
| May 27, 2024 Filed May 29, 2024 21:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 37 | $217.21 | $8,036.77 |
DisclosureSEC source: 0001127602-24-016806 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,738 Read SEC document |
| May 26, 2024 Filed May 29, 2024 21:34 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 50 | $217.21 | $10,860.50 |
DisclosureSEC source: 0001127602-24-016806 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,775 Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 20:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 808 | $267.52 | $216,156.16 |
DisclosureSEC source: 0001127602-24-009396 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,024 Read SEC document |
| March 08, 2024 Filed May 29, 2024 21:10 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 808 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-24-016791 · form4a.xml · derivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404 Underlying: Common Stock · 808 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2024 Filed May 29, 2024 21:10 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 808 | $267.52 | $216,156.16 |
DisclosureSEC source: 0001127602-24-016791 · form4a.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,825 Read SEC document |
| March 08, 2024 Filed May 29, 2024 21:10 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 808 | $267.52 | $216,156.16 |
DisclosureSEC source: 0001127602-24-016791 · form4a.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:54 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,000 | $261.35 | $261,350.00 |
DisclosureSEC source: 0001127602-24-008566 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,832 F2 · price: This transaction was executed in multiple trades at prices ranging from $261.31 to $261.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:54 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,750 | $260.88 | $456,540.00 |
DisclosureSEC source: 0001127602-24-008566 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,832 F1 · price: This transaction was executed in multiple trades at prices ranging from $260.15 to $260.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 326 | $220.28 | $71,811.28 |
DisclosureSEC source: 0001127602-24-002806 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,582 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 968 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002806 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,908 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 21:49 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 313 | $220.28 | $68,947.64 |
DisclosureSEC source: 0001127602-24-011094 · form4a.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,575 Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 21:49 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 948 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011094 · form4a.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,888 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,471 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-23-022486 · form4.xml · derivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,471 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,471 | $216.54 | $318,530.34 |
DisclosureSEC source: 0001127602-23-022486 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,940 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 1,471 | $144.67 | $212,809.57 |
DisclosureSEC source: 0001127602-23-022486 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.